Navigation Links
Recent Study Shows Leukothera™ Combined with Other Agents Has Enhanced Anti-Leukemia Effects
Date:6/27/2011

NEW BRUNSWICK, N.J., June 27, 2011 /PRNewswire/ -- Recent findings published in the scientific journal Leukemia Research (http://www.sciencedirect.com/science/article/pii/S0145212611002505), showed that when combined with standard anti-leukemia agents, the biological activity of LeukotheraTM, a drug candidate under development by Actinobac Biomed, Inc., showed synergistic anti-leukemia effects.

The outcome of these in vitro experiments demonstrated that combining LeukotheraTM with such widely employed drugs as etoposide, mitoxantrone, daunorubicin, busulfan and imatinib killed leukemia cells much more effectively than when the agents were used alone.  LeukotheraTM is a natural biologic agent that specifically targets malignant and/or inflammatory white blood cells involved in disease.  

Dr. Scott Kachlany, founder of Actinobac Biomed, explained. "Drug combination therapies for cancer are now frequently considered by oncologists due to their many advantages, which include the possibility of reducing doses of toxic chemotherapeutic agents and a lower chance of developing drug resistance," he said.  "The biological mechanism of LeukotheraTM differs from that of other cancer drugs so including it to blood cancer treatment protocols may be a highly effective strategy."

Actinobac Biomed, Inc. was founded in 2009 with financial backing from Foundation Venture Capital Group, LLC, to develop commercial products based upon technology developed at the University of Medicine and Dentistry of New Jersey.  The company has exclusively licensed the rights to develop LeukotheraTM as a therapeutic agent for the treatment of hematologic malignancies, autoimmune and inflammatory diseases and HIV infection.

"We provided early seed funding to Actinobac because we are convinced that
'/>"/>

SOURCE Foundation Venture Capital Group, LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
2. Cardium Announces Cedars-Sinai Heart Institute as the SPECT Imaging Core Lab for the Recently Announced Generx® Phase 3 Clinical Registration Study in the Russian Federation
3. Metabolic Solutions Development Company to Present Recent Findings on the Therapeutic Potential of Increasing Brown Fat in the Treatment of Diabetes at Annual American Diabetes Association Conference
4. FDA Classifies Recent Terumo CVS Recall of Coronary Ostia Cannulae as Class I Action
5. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
6. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
7. A Recent Study by ITGs Majestic Market Research Indicates a Strong Launch for Gilenya in Spite of Its Time-Consuming Initiation Process
8. In a New Audio Interview at SmallCapVoice.com, Gerard Dab, Chairman and CEO of Visual Healthcare Corp., Provides Details Regarding Recent News
9. Applied Medical Sues Covidien, Asserting Recently Issued Universal Seal Trocar Patent
10. Instacare Corp. Board of Directors Considers Recent Merger Proposal Inadequate
11. Arena Pharmaceuticals Announces First Quarter 2011 Financial Results and Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)...   Voalte , the leader in healthcare communication ... million by Ascension Ventures , Cerner Capital, Inc., ... D funding closed on July 27, 2015, bringing the ... in three years. The new capital will ... Voalte. The privately held company grew revenue by 250 ...
(Date:9/1/2015)... SAN DIEGO and BEDFORD, Mass. ... firm Robbins Arroyo LLP is investigating whether ... violated the Securities and Exchange Act of 1934.  ConforMIS ... Image-to-Implant technology platform to develop, manufacture, and sell joint ... fit each patient,s unique anatomy. View this ...
(Date:9/1/2015)... Nevro Corp. (NYSE: NVRO ), a ... solutions for the treatment of chronic pain, today announced ... the Patent Trial and Appeals Board (PTAB) in response ... filed by a unit of Boston Scientific Corporation, challenging ... 8,359,102 (the ,102 patent). The ,102 patent is one of Nevro,s 55 ...
Breaking Medicine Technology:Voalte Raises $17 Million in Series D Financing 2Voalte Raises $17 Million in Series D Financing 3Voalte Raises $17 Million in Series D Financing 4Robbins Arroyo LLP Is Investigating the Officers and Directors of ConforMIS, Inc. (CFMS) on Behalf of Shareholders 2Nevro Announces Submission of Preliminary Response to the Patent Trial and Appeals Board 2
... The Gulf Coast Regional Center of Innovation and Commercialization ... receive up to a total of $2.9 million in ...   (Logo:   http://photos.prnewswire.com/prnh/20090604/AQ28157LOGO ) ... TETF program was established by Gov. Perry and the ...
... NCIIA announced this month the winners of the inaugural ... First place and a $10,000 grant for further ... for the HydrEYE CorneOasis Contact Lens, an inexpensive solution ... due to traumatic brain injury.  In place of current ...
Cached Medicine Technology:Gulf Coast Regional Center of Innovation and Commercialization and Houston Technology Center Announce Recipients of TETF Awards 2Gulf Coast Regional Center of Innovation and Commercialization and Houston Technology Center Announce Recipients of TETF Awards 3BMEStart Competition Winners Announced 2
(Date:9/2/2015)... , ... September 02, 2015 , ... ... imaging, content, records and case management solutions and services to both government and ... Image Re-sizing and Image Clean-up utility for IBM’s Datacap document capture platform. ...
(Date:9/2/2015)... ... September 02, 2015 , ... “ G-Hold ” was ... and coolest technology products available to consumers. Amanda Forstrom, a technology expert and special ... designed for people to comfortably hold a tablet while reducing the likelihood of it ...
(Date:9/2/2015)... ... , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, has ... year. Less than 5 % of this year’s 5000 honorees share the “six-time” recognition; ... 3-year revenue growth rate of 65% sustained its most recent achievement. As an Inc. ...
(Date:9/2/2015)... ... ... Mobile working is increasingly more important, as business professionals are looking to ... are being launched, and mobile device usage as a whole is something people around ... personal lives. What's more people are expecting mobile versions of their favorite software. , ...
(Date:9/1/2015)... ... September 01, 2015 , ... For many men, the first thing they notice when they ... forced to wear a looser fitting shirt with a collar that doesn’t close against the ... between their collar and skin all day because it’s uncomfortable. Now men in suits ...
Breaking Medicine News(10 mins):Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 2Health News:EDAC Systems, Inc. announces a new version of its Image Enhancement and Image Re-Sizing utility EDAC’s PurePAGE® 3Health News:Comfortably Hold a Tablet with G-Hold Hands Free Tablet Holder 2Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
... of hope for visually- impaired patients.Retinal cell transplants can ... possibilities for them. Researchers at the University of Texas, ... a predisposition to blindness.// Experiments showed that the rats ... animals with normal vision. ,This is an ...
... Coffee is a very good stimulant in day to day ... memory performance that happens as the day progresses. During the ... adults compared to late afternoon.// For researchers at the University ... memory performance throughout the day. ,They had about ...
... that if women drink too much coffee during pregnancy can ... fits.//Studies have found that caffeine may be linked to the ... have been briefly starved of oxygen. ,A research team ... cells from the hippocampus, a part of the brain that ...
... Andhra Pradesh chief minister Chandrababu Naidu has set into ... in the port town of Vishakhapatnam. By providing world-class ... to attract global pharmaceutical companies to the city for ... 2005. The ‘Pharma City’ will be developed by private ...
... the disease gradually ended around the world. But stockpiles ... US, Russia and possibly other nations.// Recent fears of ... used to introduce the potentially deadly disease into the ... a potential outbreak. If introduced into America or Europe, ...
... a diet rich in butter and other fats, has led ... staple of the French diet. //Scientists say they have discovered ... known as polyphenols. ,Polyphenols inhibit the production ... Polyphenols in red wine decreases the amount of the peptide ...
Cached Medicine News:
... protein 4 (IGFBP-4) is a 24 kDa protein ... IGF-I and IGF-II. It is also present in ... 28 kDa. IGFBP-4 has been identified in all ... types, including fibroblasts, neuroblastoma, prostate and bone cells ...
... the adrenal gland and gonads, is the ... both of which may be subsequently converted ... activity, estimated at ~(less than or equal ... androstenedione levels often exceed testosterone in both ...
... Inhibins are heterodimeric proteins that suppress ... from the pituitary. Inhibin consists of two ... linked together. Inhibin A consists of the ... the alpha-subunit and betaB-subunit. Only the dimeric ...
... a 7.5 kDa peptide which is secreted primarily ... mitogenic and metabolic actions involved in cellular growth. ... to target cell receptors. IGF-II binds with high ... monomeric protein which also serves as the receptor ...
Medicine Products: